Wikidata

(Q61969493)

English

ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple Myeloma

clinical trial

In more languages

Statements

title
A Phase 1B/2 Multi-Center, Open Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Efficacy of ACY-1215 (RICOLINOSTAT) in Combination With Pomalidomide and Low-Dose Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma (English)
0 references
sponsor
Celgene
0 references
country
Canada
0 references
Greece
0 references
Italy
0 references
start time
1 March 2014
0 references
end time
28 July 2019
0 references
number of participants
101
0 references
research intervention
dexamethasone acetate
0 references
(RS)-cyclophosphamide
0 references
pomalidomide
0 references
thalidomide
0 references
minimum age
18 year
0 references

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit
                    Retrieved from "https://www.wikidata.org/w/index.php?title=Q61969493&oldid=2035753257"